Business context and reporting period
The filing is Sunshine Heart, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2012; the registrant is identified in the filing as Sunshine Heart, not Nuwellis. The company was developing the C-Pulse Heart Assist System for heart failure and had no commercial product sales. Its U.S. feasibility trial was complete, but the pivotal trial had not begun.
Financial results and liquidity
Unless noted, amounts are in millions of U.S. dollars. The filing presents no revenue, cost of goods sold, or gross profit for either comparable period.
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $3.356 | $3.552 | $7.462 | $6.486 |
| Operating loss | $(3.356) | $(3.552) | $(7.462) | $(6.486) |
| Net loss | $(2.622) | $(3.472) | $(6.703) | $(6.289) |
| Loss per share, basic and diluted | $(0.42) | $(0.68) | $(1.08) | $(1.24) |
| Operating cash used | Not separately stated | $(6.815) | $(6.212) |
At June 30, cash and cash equivalents were $1.772 million, versus $6.563 million at December 31, 2011. Current assets were $2.404 million and current liabilities $2.262 million, implying working capital of $0.142 million. Total liabilities were $2.262 million; the balance sheet shows no interest-bearing debt. Stockholders’ equity was $0.645 million, down from $4.596 million at year-end. Six-month investing cash use was $0.107 million; financing provided $2.068 million, primarily from an equity placement. No material capital-expenditure commitments or off-balance-sheet arrangements were reported.
Changes versus the prior comparable periods
- Q2 operating loss narrowed by about 5.5%, while six-month operating loss widened by about 15.0%.
- Q2 net loss was lower year over year, in part because of a $0.730 million Australian research-and-development tax-credit refund recorded as an income tax benefit. Six-month net loss nevertheless increased from $6.289 million to $6.703 million.
- Six-month R&D expense declined 15.3% to $3.953 million, which management attributed mainly to timing of outsourced development work. SG&A rose 92.8% to $3.509 million, reflecting stock-based compensation, professional fees, personnel and public-company/listing infrastructure.
- Cash used in operations increased to $6.815 million from $6.212 million, while cash fell $4.791 million during the first half. Interest income declined as average cash balances decreased.
Outlook, risks, and notable items
- Management expected to submit a U.S. IDE application in the second half of 2012 and projected pivotal-trial enrollment completion by the end of 2015; it did not anticipate U.S. marketing before 2017. The planned U.S. trial was described as approximately 380 patients across about 40 sites.
- The company received CE Mark approval on July 23, 2012, after quarter-end, and expected to begin a European post-market trial in the second half of 2012.
- On July 17, 2012, the company filed an S-1 for a proposed public offering of up to $28.75 million before commissions and expenses. At filing time, completion was expected in Q3 2012; proceeds were intended for the pivotal trial and general corporate purposes. The company said expected offering proceeds together with cash and other anticipated sources should fund operations for at least 12 months, but cautioned that additional capital may be needed and may not be available on acceptable terms.
- The filing highlights substantial going-concern uncertainty: continuing operations depend on raising capital and developing and commercializing the C-Pulse System. The company expected ongoing losses and had an accumulated deficit of $71.892 million at June 30.
- Key risks include reliance on a single product candidate, clinical-trial and regulatory delays or failure, dependence on third-party manufacturers and a single supplier for a specialized balloon, uncertain reimbursement and market acceptance, competition, and potential need for further dilutive financing. Q2 disclosure controls were assessed as effective; no material internal-control changes were reported.
Important facts for investors to verify
- Whether the proposed offering closed, its net proceeds, and the resulting share dilution and cash runway.
- Whether the IDE application was submitted and accepted, and whether the U.S. pivotal and European trials began on schedule.
- How quickly cash is being consumed and whether additional financing is required to complete planned trials.
- Whether the Australian R&D tax-credit refund for the period ended June 30, 2012 was ultimately available; the filing says that analysis was incomplete.
- Whether manufacturing capacity, supplier continuity, regulatory progress, and reimbursement prospects support eventual commercialization.